Review highlights m6A's role in Alzheimer's pathology and suggests new therapeutic approaches involving anti-tau treatment.
In the context of continuous social development and overnutrition, Alzheimer's disease, as a neurodegenerative disease, is becoming more and more common in the elderly and gradually younger, and there is currently no effective treatment. This article reviews the role of m6A as a target site forthe treatment of Alzheimer's disease, discusses the main case characteristics of AD, including tau hyperphosphorylation, neuroinflammation, etc., and discusses the combination of m6A regulation and anti-A/antitau drugs, m6A and anti-inflammatory treatment, etc., and reveals the new mechanism of AD pathogenesis after combining recent related research cases, and proposes that m6A can be used as a new target for AD, providing a new epitranscriptional perspective for the treatment of AD. In addition, it will promote the development of m6A-targeted drugs and provide relevant suggestions to solve the current treatment bottleneck.
No takes yet. Share an insight, caveat, or question.
Xi Zheng (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: